To determine whether the cell toxicity observed in lung cancer cells harboring ABL1 mutations can be attributed to inhibition of this kinase, we treated H1915 cells with ABL inhibitors and re‐expressed the drug‐resistant ABL1‐T315I mutant (Bixby & Talpaz, 2009). This evidence concerns the gene ABL1 and lung carcinoma.